Equities research analysts expect that BioScrip Inc (NASDAQ:BIOS) will announce sales of $171.79 million for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for BioScrip’s earnings. The lowest sales estimate is $170.49 million and the highest is $173.40 million. BioScrip posted sales of $240.12 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 28.5%. The company is scheduled to issue its next earnings report on Friday, March 2nd.
On average, analysts expect that BioScrip will report full-year sales of $171.79 million for the current year, with estimates ranging from $805.10 million to $808.00 million. For the next financial year, analysts expect that the firm will report sales of $722.13 million per share, with estimates ranging from $695.23 million to $734.93 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that that provide coverage for BioScrip.
A number of brokerages have issued reports on BIOS. Zacks Investment Research raised shares of BioScrip from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. BidaskClub raised shares of BioScrip from a “hold” rating to a “buy” rating in a report on Thursday, January 4th. SunTrust Banks set a $4.00 price target on shares of BioScrip and gave the stock a “buy” rating in a report on Thursday, December 21st. Finally, ValuEngine raised shares of BioScrip from a “sell” rating to a “hold” rating in a report on Thursday, November 30th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $3.63.
Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of BioScrip by 3.4% during the 2nd quarter. Vanguard Group Inc. now owns 4,495,029 shares of the company’s stock valued at $12,204,000 after purchasing an additional 146,980 shares in the last quarter. Gilder Gagnon Howe & Co. LLC boosted its stake in shares of BioScrip by 3.6% during the 3rd quarter. Gilder Gagnon Howe & Co. LLC now owns 15,764,337 shares of the company’s stock valued at $43,352,000 after purchasing an additional 553,201 shares in the last quarter. Skylands Capital LLC bought a new stake in shares of BioScrip during the 3rd quarter valued at about $272,000. GSA Capital Partners LLP bought a new stake in shares of BioScrip during the 3rd quarter valued at about $857,000. Finally, Northern Trust Corp boosted its stake in shares of BioScrip by 11.3% during the 2nd quarter. Northern Trust Corp now owns 1,340,339 shares of the company’s stock valued at $3,639,000 after purchasing an additional 136,187 shares in the last quarter. 84.53% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “$171.79 Million in Sales Expected for BioScrip Inc (BIOS) This Quarter” was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/12/171-79-million-in-sales-expected-for-bioscrip-inc-bios-this-quarter.html.
BioScrip Company Profile
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.